Astrana Health (NASDAQ:ASTH) Reaches New 1-Year Low – What’s Next?

Astrana Health, Inc. (NASDAQ:ASTH)’s share price hit a new 52-week low on Monday . The company traded as low as $31.20 and last traded at $31.35, with a volume of 194714 shares traded. The stock had previously closed at $32.18.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on ASTH. BTIG Research boosted their target price on shares of Astrana Health from $60.00 to $70.00 and gave the company a “buy” rating in a research report on Thursday, October 3rd. KeyCorp initiated coverage on Astrana Health in a research report on Friday, October 11th. They issued a “sector weight” rating for the company. TD Cowen started coverage on Astrana Health in a report on Monday, October 14th. They issued a “buy” rating and a $66.00 target price for the company. Macquarie upgraded shares of Astrana Health to a “hold” rating in a report on Monday, December 16th. Finally, Robert W. Baird boosted their target price on Astrana Health from $67.00 to $86.00 and gave the company an “outperform” rating in a research note on Wednesday, November 13th. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $65.17.

Astrana Health Price Performance

The company has a debt-to-equity ratio of 0.60, a current ratio of 1.91 and a quick ratio of 1.91. The stock has a market capitalization of $1.77 billion, a P/E ratio of 24.18, a price-to-earnings-growth ratio of 1.80 and a beta of 1.20. The business’s 50 day moving average price is $41.96 and its 200 day moving average price is $47.34.

Astrana Health (NASDAQ:ASTH) last posted its quarterly earnings data on Thursday, November 7th. The company reported $0.33 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.33. The firm had revenue of $478.71 million for the quarter, compared to analysts’ expectations of $462.01 million. Astrana Health had a return on equity of 9.37% and a net margin of 3.63%. During the same period in the previous year, the firm earned $0.47 EPS. Sell-side analysts forecast that Astrana Health, Inc. will post 1.16 EPS for the current year.

Institutional Trading of Astrana Health

Several hedge funds have recently made changes to their positions in ASTH. GAMMA Investing LLC bought a new position in Astrana Health in the 3rd quarter valued at $34,000. Nisa Investment Advisors LLC bought a new stake in Astrana Health during the 3rd quarter valued at $35,000. KBC Group NV bought a new position in Astrana Health in the third quarter worth about $70,000. Quarry LP purchased a new position in Astrana Health in the third quarter worth $77,000. Finally, Quest Partners LLC acquired a new stake in Astrana Health in the third quarter worth about $133,000. 52.77% of the stock is currently owned by hedge funds and other institutional investors.

Astrana Health Company Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.